Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer

Kazuyoshi Kawakami, Takashi Tunoda, Tomomi Takiguchi, Keiko Shibata, Takayuki Ohtani, Junko Kizu, Makoto Nishio, Takeshi Horai, Toshihiro Hama, Kyoji Taguchi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

No established supportive therapy to prevent and treat chemotherapy-induced peripheral neuropathy (PN) is available. Minimizing the severity of PN is therefore critical in clinical use. We aimed to determine when and how often PN occurs in association with paclitaxel plus carboplatin (PC therapy), a regimen used to treat non-small cell lung cancer, and factors that exacerbate this condition. Patients who received PC therapy for non-small cell lung cancer at the Japanese Foundation for Cancer Research, Cancer Institute Hospital, between May 20, 2009, and November 30, 2010, were included. PN was evaluated by the study pharmacist using specific questions based on the Common Terminology Criteria for Adverse Events Version 3.0. Univariate analysis was used to compare a group with no, Grade 1, or Grade 2 PN (non-serious) and a group with Grade 3 PN (serious). Analyses were conducted using the Cox proportional hazard model with patient characteristics having p ≤ 0.20 when assessed as independent variables. Of 50 patients, 38 (76.0%) developed PN by day 6 of the first course of anticancer treatment. Grade 3 PN had an incidence of 25.0% in the fourth course. In multivariate analysis with the Cox proportional hazard model, pack-year [hazard ratio = 1.029; 95% confidence interval (CI): 1.009-1.050, p = 0.005] and creatinine clearance (hazard ratio = 0.957; 95% CI: 0.920-0.996, p = 0.031) were significant factors. A high pack-year and a low creatinine clearance exacerbated PN in patients treated with PC. PN must be carefully evaluated in patients with exacerbating factors.

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalOncology Research
Volume20
Issue number4
DOIs
Publication statusPublished - 2012

Fingerprint

Carboplatin
Peripheral Nervous System Diseases
Paclitaxel
Non-Small Cell Lung Carcinoma
Proportional Hazards Models
Creatinine
Confidence Intervals
Cancer Care Facilities
Therapeutics
Pharmacists
Terminology
Multivariate Analysis
Drug Therapy

Keywords

  • Cox proportional hazard analysis
  • Creatinine clearance
  • Non-small cell lung cancer
  • Pack-year
  • Paclitaxel + carboplatin ± bevacizumab
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kawakami, K., Tunoda, T., Takiguchi, T., Shibata, K., Ohtani, T., Kizu, J., ... Taguchi, K. (2012). Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncology Research, 20(4), 179-185. https://doi.org/10.3727/096504012X13522227232192

Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. / Kawakami, Kazuyoshi; Tunoda, Takashi; Takiguchi, Tomomi; Shibata, Keiko; Ohtani, Takayuki; Kizu, Junko; Nishio, Makoto; Horai, Takeshi; Hama, Toshihiro; Taguchi, Kyoji.

In: Oncology Research, Vol. 20, No. 4, 2012, p. 179-185.

Research output: Contribution to journalArticle

Kawakami, K, Tunoda, T, Takiguchi, T, Shibata, K, Ohtani, T, Kizu, J, Nishio, M, Horai, T, Hama, T & Taguchi, K 2012, 'Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer', Oncology Research, vol. 20, no. 4, pp. 179-185. https://doi.org/10.3727/096504012X13522227232192
Kawakami, Kazuyoshi ; Tunoda, Takashi ; Takiguchi, Tomomi ; Shibata, Keiko ; Ohtani, Takayuki ; Kizu, Junko ; Nishio, Makoto ; Horai, Takeshi ; Hama, Toshihiro ; Taguchi, Kyoji. / Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. In: Oncology Research. 2012 ; Vol. 20, No. 4. pp. 179-185.
@article{bd904419435d4933a73a39641fb62de5,
title = "Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer",
abstract = "No established supportive therapy to prevent and treat chemotherapy-induced peripheral neuropathy (PN) is available. Minimizing the severity of PN is therefore critical in clinical use. We aimed to determine when and how often PN occurs in association with paclitaxel plus carboplatin (PC therapy), a regimen used to treat non-small cell lung cancer, and factors that exacerbate this condition. Patients who received PC therapy for non-small cell lung cancer at the Japanese Foundation for Cancer Research, Cancer Institute Hospital, between May 20, 2009, and November 30, 2010, were included. PN was evaluated by the study pharmacist using specific questions based on the Common Terminology Criteria for Adverse Events Version 3.0. Univariate analysis was used to compare a group with no, Grade 1, or Grade 2 PN (non-serious) and a group with Grade 3 PN (serious). Analyses were conducted using the Cox proportional hazard model with patient characteristics having p ≤ 0.20 when assessed as independent variables. Of 50 patients, 38 (76.0{\%}) developed PN by day 6 of the first course of anticancer treatment. Grade 3 PN had an incidence of 25.0{\%} in the fourth course. In multivariate analysis with the Cox proportional hazard model, pack-year [hazard ratio = 1.029; 95{\%} confidence interval (CI): 1.009-1.050, p = 0.005] and creatinine clearance (hazard ratio = 0.957; 95{\%} CI: 0.920-0.996, p = 0.031) were significant factors. A high pack-year and a low creatinine clearance exacerbated PN in patients treated with PC. PN must be carefully evaluated in patients with exacerbating factors.",
keywords = "Cox proportional hazard analysis, Creatinine clearance, Non-small cell lung cancer, Pack-year, Paclitaxel + carboplatin ± bevacizumab, Peripheral neuropathy",
author = "Kazuyoshi Kawakami and Takashi Tunoda and Tomomi Takiguchi and Keiko Shibata and Takayuki Ohtani and Junko Kizu and Makoto Nishio and Takeshi Horai and Toshihiro Hama and Kyoji Taguchi",
year = "2012",
doi = "10.3727/096504012X13522227232192",
language = "English",
volume = "20",
pages = "179--185",
journal = "Oncology Research",
issn = "0965-0407",
publisher = "Cognizant Communication Corporation",
number = "4",

}

TY - JOUR

T1 - Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer

AU - Kawakami, Kazuyoshi

AU - Tunoda, Takashi

AU - Takiguchi, Tomomi

AU - Shibata, Keiko

AU - Ohtani, Takayuki

AU - Kizu, Junko

AU - Nishio, Makoto

AU - Horai, Takeshi

AU - Hama, Toshihiro

AU - Taguchi, Kyoji

PY - 2012

Y1 - 2012

N2 - No established supportive therapy to prevent and treat chemotherapy-induced peripheral neuropathy (PN) is available. Minimizing the severity of PN is therefore critical in clinical use. We aimed to determine when and how often PN occurs in association with paclitaxel plus carboplatin (PC therapy), a regimen used to treat non-small cell lung cancer, and factors that exacerbate this condition. Patients who received PC therapy for non-small cell lung cancer at the Japanese Foundation for Cancer Research, Cancer Institute Hospital, between May 20, 2009, and November 30, 2010, were included. PN was evaluated by the study pharmacist using specific questions based on the Common Terminology Criteria for Adverse Events Version 3.0. Univariate analysis was used to compare a group with no, Grade 1, or Grade 2 PN (non-serious) and a group with Grade 3 PN (serious). Analyses were conducted using the Cox proportional hazard model with patient characteristics having p ≤ 0.20 when assessed as independent variables. Of 50 patients, 38 (76.0%) developed PN by day 6 of the first course of anticancer treatment. Grade 3 PN had an incidence of 25.0% in the fourth course. In multivariate analysis with the Cox proportional hazard model, pack-year [hazard ratio = 1.029; 95% confidence interval (CI): 1.009-1.050, p = 0.005] and creatinine clearance (hazard ratio = 0.957; 95% CI: 0.920-0.996, p = 0.031) were significant factors. A high pack-year and a low creatinine clearance exacerbated PN in patients treated with PC. PN must be carefully evaluated in patients with exacerbating factors.

AB - No established supportive therapy to prevent and treat chemotherapy-induced peripheral neuropathy (PN) is available. Minimizing the severity of PN is therefore critical in clinical use. We aimed to determine when and how often PN occurs in association with paclitaxel plus carboplatin (PC therapy), a regimen used to treat non-small cell lung cancer, and factors that exacerbate this condition. Patients who received PC therapy for non-small cell lung cancer at the Japanese Foundation for Cancer Research, Cancer Institute Hospital, between May 20, 2009, and November 30, 2010, were included. PN was evaluated by the study pharmacist using specific questions based on the Common Terminology Criteria for Adverse Events Version 3.0. Univariate analysis was used to compare a group with no, Grade 1, or Grade 2 PN (non-serious) and a group with Grade 3 PN (serious). Analyses were conducted using the Cox proportional hazard model with patient characteristics having p ≤ 0.20 when assessed as independent variables. Of 50 patients, 38 (76.0%) developed PN by day 6 of the first course of anticancer treatment. Grade 3 PN had an incidence of 25.0% in the fourth course. In multivariate analysis with the Cox proportional hazard model, pack-year [hazard ratio = 1.029; 95% confidence interval (CI): 1.009-1.050, p = 0.005] and creatinine clearance (hazard ratio = 0.957; 95% CI: 0.920-0.996, p = 0.031) were significant factors. A high pack-year and a low creatinine clearance exacerbated PN in patients treated with PC. PN must be carefully evaluated in patients with exacerbating factors.

KW - Cox proportional hazard analysis

KW - Creatinine clearance

KW - Non-small cell lung cancer

KW - Pack-year

KW - Paclitaxel + carboplatin ± bevacizumab

KW - Peripheral neuropathy

UR - http://www.scopus.com/inward/record.url?scp=84871882087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871882087&partnerID=8YFLogxK

U2 - 10.3727/096504012X13522227232192

DO - 10.3727/096504012X13522227232192

M3 - Article

C2 - 23461065

AN - SCOPUS:84871882087

VL - 20

SP - 179

EP - 185

JO - Oncology Research

JF - Oncology Research

SN - 0965-0407

IS - 4

ER -